A laboratory researcher in a file photo.
Credit: Reuters/FileBy Jeremy PelofskyWASHINGTON | Fri 29 april 2011 2: 53 pm EDT
WASHINGTON (Reuters)-a Court of Appeal ruled on Friday that the Obama administration can continue to use federal money for human embryonic stem cell research, a possible avenue to new treatments for many medical conditions to finance.
The Court a ruling by a federal judge who found that the u.s. National Institutes of Health (NIH) guidelines on such research violated the law because embryos were destroyed and the other researchers working with adult stem cells on appeal a disadvantage destroyed to win federal grants.
Opponents of human embryonic stem cell research, including many religious conservatives, argue that it is unacceptable because it destroys human embryos.
Such stem cells from human embryos and old days can be any type of cell in the body produce. Scientists hope to be able to use them to address spinal cord injuries, cancer, diabetes, and diseases such as Alzheimer's and Parkinson's disease.
U.s. District Judge Royce Lamberth last August blocked the taxpayer funding. His decision was on hold pending appeal so that federal money flows after the White House investigation would cost millions of dollars lost warned if stopped.
A panel of three judges of the u.s. Court of appeals for the District of Columbia Circuit, all appointed by Republican presidents, voted 2-1 to vacate Lamberth of warrant, say that the challengers were unlikely to win on the merits.
The US legislation "ambiguous" and "did not prohibit funding a research project in which a ESC (embryonic stem cells) will be used," said the majority opinion.
"This is a red-letter day--not just for science but for the hopes of thousands of patients and their families who rely on NIH-funded scientists life-saving discoveries and therapies of stem cell research can continue," said NIH Director Francis Collins in a statement.
Shortly after her appointment in 2009, President Barack Obama expanded federal funding of research with human embryonic stem cells in the hope that it will lead to treatments for diseases.
In an attempt to answer critics, Obama directed the NIH to come up with an ethical process for paying specifically for such research, that the embryos from fertility clinics and were otherwise thrown away.
Since the appellate ruling on the injunction that Lamberth was issued, the focus now turns back to his courtroom where the social partners on the specific merits of or the stem cell guidelines have argued are legal.
The American legislation on embryonic stem cell research funding prohibits the NIH funding the creation of human embryos for research or investigation in which a human embryo is destroyed, leading the judges to argue about his true intention.
' LINGUISTIC JUJITSU '
Judge Douglas Ginsburg, appointed by President Ronald Reagan, wrote that the "very reasonable" was for the NIH to interpret the law "enforceable funding for research using cell lines derived without federal funding," even if it bars financing for the derivation of additional rules
In a dissenting opinion, judge Karen LeCraft Henderson, appointed by President George H.W. Bush, said the Federal law was clear about the ban on funding for human embryonic stem cell research and that the Court majority engaging in "linguistic Jujitsu" was to back it.
The case arose from two researchers who work with embryonic stem cells and block this funding sued. They argued that they were in danger of being squeezed out of federal subsidies for their own work with adult stem cells, which do not involve the destruction of embryos.
The researchers, Dr. James Sherley, a biological engineer at Boston Biomedical Research Institute, and Theresa Deisher, Washington-based biotechnology AVM, the pronunciation for the full Appeals Court, a lawyer involved in the case said profession.
Samuel Casey of the right of life Project, a lawyer involved in the challenge, said he was disappointed, but not surprised by the ruling, and was glad it was narrow.
Bernard Siegel, Executive Director of the genetics Policy Institute and founder of the stem cell Action Coalition, hailed the decision as a cloud of uncertainty to lift on research.
"This case is not by any stretch but this lifts the cloud temporarily," he told Reuters. "This is still fundamental research that must take place before we can further the full and to translate to cures. For them to keep it back in 2010, 2011 and 2012 would be a travesty for patients. "
Gary Rabin, chief executive of Advanced Cell Technology, which is the development of treatments for two eye diseases using embryonic stem cells and approval to start human clinical trials has gotten, praised the ruling.
"You're at the beginning of what will eventually be a groundswell of opportunities within the community of embryonic stem cells," he said. "We believe that this is the first step for us to ensure that our cell lines affordable by the Government will be."
(Additional reporting by James Vicini and Tabassum Zakaria in Washington and Bill Berkrot in New York, edit by Will Dunham)